SCHEMBL30708362

SCHEMBL30708362

COc1ccc(CN(Cc2ccc(OC)cc2)c2ccc(C(F)(F)F)c(Cl)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.42
XPO1 O14980 3/20 0.39
LMNA P02545 3/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
PIK3CA P42336 1/20 0.39
CYP1A2 P05177 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1860490 1.00 PIK3CD (0.42) PIK3CDXPO1LMNAMAPTALDH1A1
SCHEMBL29666619 0.88 ALDH1A1 (0.42) XPO1LMNAMAPTALDH1A1MEN1
SCHEMBL24460923 0.88 ALDH1A1 (0.42) XPO1LMNAMAPTALDH1A1MEN1
SCHEMBL26694482 0.85 MEN1 (0.42) PIK3CDLMNAMAPTALDH1A1MEN1
SCHEMBL24649338 0.84 LMNA (0.39) PIK3CDLMNAMAPTALDH1A1MEN1
SCHEMBL2421138 0.83 XPO1 (0.47) XPO1ALDH1A1MEN1KMT2AGAA
SCHEMBL31715974 0.82 XPO1 (0.40) XPO1ALDH1A1SMN1; SMN2
SCHEMBL2974934 0.82 XPO1 (0.40) XPO1ALDH1A1SMN1; SMN2
SCHEMBL1862955 0.81 LMNA (0.40) PIK3CDLMNAMAPTALDH1A1MEN1
SCHEMBL15232439 0.81 PIK3CA (0.44) PIK3CDLMNAMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547666-A1 METHODS FOR TREATMENT OF CANCER Frontier Medicines Corporation (US) 2025-05-07 EP disclosed
WO-2024006445-A1 METHODS FOR TREATMENT OF CANCER FRONTIER MEDICINES CORPORATION (US) 2024-01-04 WO disclosed